These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36639711)

  • 1. CircIFNGR2 enhances proliferation and migration of CRC and induces cetuximab resistance by indirectly targeting KRAS via sponging to MiR-30b.
    Zhang Q; Zheng Y; Liu J; Tang X; Wang Y; Li X; Li H; Zhou X; Tang S; Tang Y; Wang X; He H; Li T
    Cell Death Dis; 2023 Jan; 14(1):24. PubMed ID: 36639711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
    Weng WH; Leung WH; Pang YJ; Hsu HH
    Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
    Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
    Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
    Chen D; Huang X; Cai J; Guo S; Qian W; Wery JP; Li QX
    Oncotarget; 2015 Dec; 6(38):40815-21. PubMed ID: 26512781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.
    Liao WT; Ye YP; Zhang NJ; Li TT; Wang SY; Cui YM; Qi L; Wu P; Jiao HL; Xie YJ; Zhang C; Wang JX; Ding YQ
    J Pathol; 2014 Mar; 232(4):415-27. PubMed ID: 24293274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
    Arriga R; Caratelli S; Lanzilli G; Ottaviani A; Cenciarelli C; Sconocchia T; Spagnoli GC; Iezzi G; Roselli M; Lauro D; Coppola A; Dotti G; Ferrone S; Sconocchia G
    Int J Cancer; 2020 May; 146(9):2531-2538. PubMed ID: 31396956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data.
    Guo GF; Wang YX; Zhang YJ; Chen XX; Lu JB; Wang HH; Jiang C; Qiu HQ; Xia LP
    World J Gastroenterol; 2019 Apr; 25(15):1840-1853. PubMed ID: 31057298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
    Nakadate Y; Kodera Y; Kitamura Y; Shirasawa S; Tachibana T; Tamura T; Koizumi F
    Int J Cancer; 2014 May; 134(9):2146-55. PubMed ID: 24136682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
    Zhang H; Yuan L; Liu L; Yan C; Cheng J; Fu Q; Tong Z; Jiang W; Zheng Y; Zhao P; Zhang G; Fang W
    BMC Cancer; 2020 May; 20(1):416. PubMed ID: 32404198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway.
    Pei Q; Liu GS; Li HP; Zhang Y; Xu XC; Gao H; Zhang W; Li T
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9871-9881. PubMed ID: 31799655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines.
    Kim S; Kim N; Kang K; Kim W; Won J; Cho J
    Cells; 2019 Aug; 8(8):. PubMed ID: 31409052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer.
    Yuan Y; Sun X; Liu M; Li S; Dong Y; Hu K; Zhang J; Xu B; Ma S; Jiang H; Hou P; Lin Y; Gan L; Liu T
    Acta Biochim Biophys Sin (Shanghai); 2023 Jun; 55(9):1467-1478. PubMed ID: 37310146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 18. Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab.
    Bellier J; Nokin MJ; Caprasse M; Tiamiou A; Blomme A; Scheijen JL; Koopmansch B; MacKay GM; Chiavarina B; Costanza B; Rademaker G; Durieux F; Agirman F; Maloujahmoum N; Cusumano PG; Lovinfosse P; Leung HY; Lambert F; Bours V; Schalkwijk CG; Hustinx R; Peulen O; Castronovo V; Bellahcène A
    Cell Rep; 2020 Feb; 30(5):1400-1416.e6. PubMed ID: 32023458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA
    Xu YJ; Zhao JM; Ni XF; Wang W; Hu WW; Wu CP
    Epigenomics; 2021 Aug; 13(16):1281-1297. PubMed ID: 34523356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.